Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.

@article{Barbaro2007VisceralFA,
  title={Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.},
  author={G. Barbaro},
  journal={Current pharmaceutical design},
  year={2007},
  volume={13 21},
  pages={
          2208-13
        }
}
  • G. Barbaro
  • Published 2007 in Current pharmaceutical design
HIV-associated lipodystrophy or lipoatrophy, unreported before the introduction of highly active antiretroviral therapy (HAART), was first described in 1998, and has a prevalence ranging from 18% to 83%. As in genetic lipodystrophy syndromes, fat redistribution may precede the development of metabolic complications (dyslipidemia, insulin resistance) in HIV-infected patients receiving HAART. The pathogenesis of HAART-associated lipodystrophy and metabolic syndrome is complex and a number of… CONTINUE READING
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…